RedHill Biopharma Ltd. (NASDAQ:RDHL) saw an upside of 5.26% to close Tuesday at $0.18 after adding $0.01 on the day. The 5-day average trading volume is 3,152,460 shares of the company’s common stock. It has gained $0.1900 in the past week and touched a new high 1 time within the past 5 days. An average of 6,330,985 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 3,782,188.
RDHL’s 1-month performance is 9.76% or $0.0215 on its low of $0.1260 reached on 12/28/22. The company’s shares have touched a 52-week low of $0.13 and high of $3.27, with the stock’s rally to the 52-week high happening on 01/13/23. YTD, RDHL has achieved 28.30% or $0.0397 and has reached a new high 2 times. However, the current price is down -94.50% from the 52-week high price.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our 5 Best Growth Stocks To Own For 2023.
RDHL stock has a beta of 2.13. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 0.23.
RedHill Biopharma Ltd.’s quick ratio for the period ended June 29 was 0.40, with the current ratio over the same period at 0.40.. In terms of profitability, the gross margin trailing 12 months is 50.50%. The firm’s gross profit as reported stood at $36.35 million against revenue of $85.76 million.
For the quarterly period ending June 29 this year, Net income and sales went down compared to those figures reported in the previous quarter. Net income grew 22.07% to $97.74 million, while revenue of $0.0 was 100.0% off the previous quarter. Analysts expected RDHL to announce -$0.03 per share in earnings in its latest quarter, but it posted -$0.2, representing a -566.70% surprise. EBITDA for the quarter stood at more than -$5.02 million. RDHL stock balance sheet for the quarter ending June 29 shows that total liabilities totaled 203.22 million, with total debt at $120.83 million.
Let’s look briefly at RedHill Biopharma Ltd. (RDHL) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 24 January was 50.95% to suggest the stock is trending Neutral, with historical volatility in this time period at 80.19%.
The stock’s 5-day moving average is $0.1742, reflecting a -6.10% or -$0.0117 change from its current price. RDHL is currently trading +12.08% above its 20-day SMA, -80.53% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 by -70.76% and SMA200 by-92.97%.
Stochastic %K and %D was 47.41% and 50.22% and the average true range (ATR) pointed at 0.0159. The RSI (14) points at 42.25%, while the 14-day stochastic is at 53.68% with the period’s ATR at 0.0196. The stock’s 9-day MACD Oscillator is pointing at -0.0044 and 0.0003 on the 14-day charts.
In the most recent analyst report for RedHill Biopharma Ltd. (NASDAQ: RDHL), Cantor Fitzgerald launched coverage with an Overweight rating. Analysts offering their rating for RDHL stock have a consensus rating for the stock as Buy. Currently, 0 brokerage advisors rate RDHL as a “sell,”, while 0 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 0 rates the stock as overweight while 1 have offered a “buy” rating.
What is RDHL’s price target for the next 12 months?
Analysts have a consensus price target ranging from a low of $1.00 and a high of $1.00, with their median price target at $1.00. Looking at these predictions, the average price target given by analysts is for RedHill Biopharma Ltd. (RDHL) stock is $1.00.